<!DOCTYPE html>
<html lang="en">
<head>
  
  
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    
    
    <link rel="canonical" href="https://jzpero.github.io/mednotes/Cardiology/Hypertension/">
    <link rel="shortcut icon" href="../../img/favicon.ico">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=0" />
    <title>Blood Pressure Thresholds and Targets for Pharm Therapy - MedNotes</title>
    <link href="../../css/bootstrap-3.3.7.min.css" rel="stylesheet">
    <link href="../../css/font-awesome-4.7.0.css" rel="stylesheet">
    <link href="../../css/base.css" rel="stylesheet">
    <link rel="stylesheet" href="../../css/highlight.css">
    <!-- HTML5 shim and Respond.js IE8 support of HTML5 elements and media queries -->
    <!--[if lt IE 9]>
        <script src="https://oss.maxcdn.com/libs/html5shiv/3.7.0/html5shiv.js"></script>
        <script src="https://oss.maxcdn.com/libs/respond.js/1.3.0/respond.min.js"></script>
    <![endif]-->

    <script src="../../js/jquery-3.2.1.min.js"></script>
    <script src="../../js/bootstrap-3.3.7.min.js"></script>
    <script src="../../js/highlight.pack.js"></script>
    
    <base target="_top">
    <script>
      var base_url = '../..';
      var is_top_frame = false;
        
        var pageToc = [
          {title: "Blood Pressure Thresholds and Targets for Pharm Therapy", url: "#_top", children: [
          ]},
          {title: "Pharmacotherapy", url: "#pharmacotherapy", children: [
              {title: "First-Line Therapy", url: "#first-line-therapy" },
              {title: "Second-Line Therapy", url: "#second-line-therapy" },
              {title: "Specific Population Therapies", url: "#specific-population-therapies" },
          ]},
          {title: "Lifestyle Interventions", url: "#lifestyle-interventions", children: [
          ]},
          {title: "Major Hypertension Trials", url: "#major-hypertension-trials", children: [
              {title: "SHEP (1991)", url: "#shep-1991" },
              {title: "DASH (1997)", url: "#dash-1997" },
              {title: "ALLHAT (2002)", url: "#allhat-2002" },
              {title: "ACCOMPLISH (2008)", url: "#accomplish-2008" },
              {title: "ACCORD (2010)", url: "#accord-2010" },
              {title: "SPRINT (2015)", url: "#sprint-2015" },
          ]},
          {title: "Secondary Hypertension", url: "#secondary-hypertension", children: [
              {title: "Causes", url: "#causes" },
          ]},
          {title: "References", url: "#references", children: [
          ]},
        ];

    </script>
    <script src="../../js/base.js"></script> 
</head>

<body>
<script>
if (is_top_frame) { $('body').addClass('wm-top-page'); }
</script>



<div class="container-fluid wm-page-content">
  <a name="_top"></a>
    

    
    
      
    

  <div class="row wm-article-nav-buttons" role="navigation" aria-label="navigation">
    
    <div class="wm-article-nav pull-right">
      <a href="../Hypertriglyceridemia/" class="btn btn-xs btn-default pull-right">
        Next
        <i class="fa fa-chevron-right" aria-hidden="true"></i>
      </a>
      <a href="../Hypertriglyceridemia/" class="btn btn-xs btn-link">
        Hypertriglyceridemia
      </a>
    </div>
    
    <div class="wm-article-nav">
      <a href="../Congenital%20Heart%20Disease/" class="btn btn-xs btn-default pull-left">
        <i class="fa fa-chevron-left" aria-hidden="true"></i>
        Previous</a><a href="../Congenital%20Heart%20Disease/" class="btn btn-xs btn-link">
        Congenital Heart Disease
      </a>
    </div>
    
  </div>

    

    <h1 id="blood-pressure-thresholds-and-targets-for-pharm-therapy">Blood Pressure Thresholds and Targets for Pharm Therapy</h1>
<table>
<thead>
<tr>
<th>Population</th>
<th>Threshold</th>
<th>Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Macrovascular disease</td>
<td>140/90</td>
<td>&lt;140/90</td>
</tr>
<tr>
<td>Diabetes</td>
<td>130/80</td>
<td>&lt;130/80</td>
</tr>
<tr>
<td>High risk (SPRINT)</td>
<td>SBP 130 and other risk factors (see below)</td>
<td>SBP &lt; 120</td>
</tr>
<tr>
<td><a href="../Nephrology/Polycystic%20Kidney%20Disease%20(PKD).md">PKD</a></td>
<td>HALT-<a href="../../Nephrology/Causes%20of%20Renal%20Failure/Polycystic%20Kidney%20Disease%20%28PKD%29/">PKD</a> population</td>
<td>SBP &lt; 95-110</td>
</tr>
<tr>
<td>Non-SPRINT CKD</td>
<td></td>
<td>SBP &lt; 140</td>
</tr>
<tr>
<td>History of spontaneous <a href="../../Critical%20Care/Neuro%20Critical%20Care/Intracranial%20Hemorrhage/">ICH</a></td>
<td></td>
<td>&lt;130/80</td>
</tr>
</tbody>
</table>
<div class="admonition info">
<p class="admonition-title"><strong>SPRINT, or "High-Risk" Population:</strong></p>
<p>SBP &gt; 130 and one of:
1) Age 50+ with clinical or subclinical CVD, eGFR 20-60, proteinuria &lt; 1 g/d, 10-year CV risk 15%+
2) Age 75+</p>
</div>
<h1 id="pharmacotherapy">Pharmacotherapy</h1>
<h2 id="first-line-therapy">First-Line Therapy</h2>
<ul>
<li>Single-Pill Combinations (SPCs):<ul>
<li>ACEi + CCB preferred.</li>
<li>ARB + CCB</li>
<li>ACE/ARB + diuretic</li>
</ul>
</li>
<li>Diuretics: long-acting TDs (chlorthalidone, indapamide) preferred over HCTZ</li>
<li>ACE/ARB</li>
<li>Long-acting CCB</li>
<li>Beta-blockers (if young or with CVD)</li>
</ul>
<h2 id="second-line-therapy">Second-Line Therapy</h2>
<ul>
<li>add on drugs from the first-line choices:<ul>
<li>thiazide + DHP-CCB</li>
<li>DHP-CCB + ACEi</li>
</ul>
</li>
<li>avoid:<ul>
<li>ACE + ARBC</li>
<li>Dilt/verapamil + Beta blocker</li>
</ul>
</li>
</ul>
<h2 id="specific-population-therapies">Specific Population Therapies</h2>
<table>
<thead>
<tr>
<th>Population</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes</td>
<td>ACE/ARB (especially with albuminuria or CKD), DHP-CCB, thiazide. If combination therapy with ACEi is needed, a DHP-CCB is preferred over a thiazide.</td>
</tr>
</tbody>
</table>
<p><img alt="" src="../_attachments/Pasted%20image%2020221008235442.png" />
<img alt="" src="../_attachments/Pasted%20image%2020221008235437.png" /></p>
<h1 id="lifestyle-interventions">Lifestyle Interventions</h1>
<table>
<thead>
<tr>
<th>Intervention</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exercise</td>
<td>30-60 minutes, moderate intensity, 4-7 days weekly</td>
</tr>
<tr>
<td>Weight</td>
<td>BMI 18.5-25, waist circumference &lt;102 cm (M) &lt;88 cm (F) for HTN prevention</td>
</tr>
<tr>
<td>Alcohol</td>
<td>Abstain from alcohol</td>
</tr>
<tr>
<td>Diet</td>
<td>DASH diet</td>
</tr>
<tr>
<td>Salt intake</td>
<td>&lt;5 grams daily, &lt;2 grams sodium</td>
</tr>
<tr>
<td>Potassium supplementation</td>
<td>Consider if not at risk of hyperK</td>
</tr>
<tr>
<td>Stress reduction</td>
<td>CBT, relaxation, etc.</td>
</tr>
<tr>
<td>Smoking cessation</td>
<td>Pharmacotherapy + counselling</td>
</tr>
<tr>
<td>Ca++/Mg++ supplementation</td>
<td>None</td>
</tr>
</tbody>
</table>
<h1 id="major-hypertension-trials">Major Hypertension Trials</h1>
<p><img alt="" src="../_attachments/fcvm-03-00003-t001.jpg" /></p>
<h2 id="shep-1991">SHEP (1991)</h2>
<h2 id="dash-1997">DASH (1997)</h2>
<h2 id="allhat-2002">ALLHAT (2002)</h2>
<p>RCT to determine whether the occurrence of fatal CHD or nonfatal myocardial infarction (<a href="../Ischemic%20Heart%20Disease/Thrombotic%20Disease/ACS/">MI</a>) is lower for high-risk patients with hypertension treated with amlodipine, lisinopril, doxazosin, or chlorthalidone.</p>
<p>Upon analysis of the data, the primary outcome, fatal coronary artery disease or nonfatal <a href="../Ischemic%20Heart%20Disease/Thrombotic%20Disease/ACS/">MI</a> at 6 years, was similar among all groups. There was also no significant difference in all-cause mortality, a secondary outcome, among the groups.
- When comparing amlodipine with chlorthalidone, the amlodipine group had a 38% higher risk of heart failure (HF) (P&lt;.001) and a 35% higher risk of hospitalized/fatal HF (P&lt;.001).
- When comparing lisinopril with chlorthalidone, the lisinopril group had a 15% higher risk for stroke (P=.02), a 10% higher risk of combined cardiovascular disease (CVD) (p&lt;0.001), a 19% higher risk of HF (P&lt;.001), and an 11% higher risk of hospitalized/treated angina (P=.01).</p>
<p>As a result, <strong>the authors of the study concluded that thiazide-type diuretics are superior in preventing CVD</strong> and recommended that they be preferred for first-step antihypertensive therapy. Because of results from the study, the JNC 7 hypertension guidelines recommended that diuretics should be initiated in stage I hypertension.</p>
<h2 id="accomplish-2008">ACCOMPLISH (2008)</h2>
<p>In patients with hypertension at high risk for cardiovascular complications, the combination of benazepril-amlodipine is superior to benazepril-hydrochlorothiazide in reducing cardiovascular events.</p>
<h2 id="accord-2010">ACCORD (2010)</h2>
<p>In diabetic, is SBP &lt; 120 better than &lt; 140? No significant difference in mortality, total CV events, or renal protection.</p>
<h2 id="sprint-2015">SPRINT (2015)</h2>
<p>Among patients at high risk for cardiovascular events but without diabetes, intensive blood pressure control to a target SBP &lt;120 mmHg improves cardiovascular outcomes but increases the rates of some adverse events.</p>
<h1 id="secondary-hypertension">Secondary Hypertension</h1>
<h2 id="causes">Causes</h2>
<ol>
<li><a href="../../Nephrology/Renovascular%20Hypertension/">Renovascular Hypertension</a></li>
<li>Endocrine (pheochromocytoma, thyroid disease)</li>
<li><a href="../../Endocrinology/HPA%20Axis%20Disorders/Primary%20hyperaldosteronism/">Primary hyperaldosteronism</a></li>
<li><a href="../../Respirology/Sleep%20Medicine/Obstructive%20Sleep%20Apnea/">Obstructive Sleep Apnea</a></li>
</ol>
<h1 id="references">References</h1>
<ol>
<li><a href="https://www.pharmacytimes.com/view/5-blood-pressure-studies-every-pharmacist-should-know">5 Blood Pressure Studies Pharmacists Should Know About</a></li>
<li><a href="https://www.frontiersin.org/articles/10.3389/fcvm.2016.00003/full">Frontiers | Timeline of History of Hypertension Treatment</a></li>
<li>Hypertension 2020 Guidelines</li>
<li>IM Review 2021 - Nephrology Slides </li>
</ol>

  <br>
    

    
    
      
    

  <div class="row wm-article-nav-buttons" role="navigation" aria-label="navigation">
    
    <div class="wm-article-nav pull-right">
      <a href="../Hypertriglyceridemia/" class="btn btn-xs btn-default pull-right">
        Next
        <i class="fa fa-chevron-right" aria-hidden="true"></i>
      </a>
      <a href="../Hypertriglyceridemia/" class="btn btn-xs btn-link">
        Hypertriglyceridemia
      </a>
    </div>
    
    <div class="wm-article-nav">
      <a href="../Congenital%20Heart%20Disease/" class="btn btn-xs btn-default pull-left">
        <i class="fa fa-chevron-left" aria-hidden="true"></i>
        Previous</a><a href="../Congenital%20Heart%20Disease/" class="btn btn-xs btn-link">
        Congenital Heart Disease
      </a>
    </div>
    
  </div>

    <br>
</div>

<footer class="container-fluid wm-page-content">
  <p>Documentation built with <a href="https://www.mkdocs.org/">MkDocs</a> using <a href="https://github.com/gristlabs/mkdocs-windmill">Windmill</a> theme by Grist Labs.</p>
</footer>

</body>
</html>